Alrizomadlin Targets MDM2 in Salivary Cancers Trial
In a groundbreaking advancement in targeted cancer therapy, researchers have unveiled promising early clinical trial results for Alrizomadlin (APG-115), a novel MDM2 inhibitor, specifically targeting...















